Back to top
October 7, 2016
Milken Institute Center for Strategic Philanthropy Releases "Epilepsy Giving Smarter Guide"
Research

Patients with treatment-resistant epilepsy, including very young children, face uncontrollable seizures; lifelong, negative impact; and are 20 times more likely to experience mortality. The Milken Institute Center for Strategic Philanthropy just released its "Epilepsy Giving Smarter Guide" to inform strategic decisions with philanthropic investments. CURE is proud to be acknowledged in the report.

Read the full report

Related News

February 21, 2018
GW Pharmaceuticals Announces That Pipeline Compound...

GW Pharmaceuticals announced that a Phase 2a proof-of-concept study of a pipeline compound GWP42006 in adult patients with focal seizures did...

February 20, 2018
News from Abroad: Xenon Pharmaceuticals Advances Second...

Xenon Pharmaceuticals Inc. announced the initiation of a Phase 1 clinical trial of its proprietary epilepsy product candidate, XEN901.

February 19, 2018
Maternal use of epilepsy drug may decrease school...

Pregnant women who used valproate had children with significantly lower school performance vs. children who were exposed to lamotrigine or not...